The growing prevalence of growth hormone deficiency is driving the growth of the global somatropin market growth. According to an article published in the Springer Nature journal in February 2017, the prevalence of growth hormone deficiency in children is within the range of 1.8 to 2.9 per 10,000 in Europe and the U.S. Increasing approval of various somatropin products by regulatory authorities such as the U.S. Food and Drug Administration (FDA) is again fostering the growth of the market. For instance, in July 2018, Ferring Pharmaceuticals Inc. received approval from the U.S. Food and Drug Administration for ZOMACTON, a somatropin injection, for the following additional pediatric indications. Short stature due to Turner syndrome, Idiopathic short stature (ISS), and Short stature born small for gestational age (SGA) with no catch-up growth by 2 to 4 years.
North America is expected to hold the dominant position in the global somatropin market due to growing FDA approval for a new product launch. For instance, in September 2020, The U.S. Food and Drug Administration approved Sogroya (somapacitan) for adults with growth hormone deficiency. Sogroya is the first human growth hormone (hGH) therapy that adult patients only take once a week by injection under the skin; other FDA-approved hGH formulations for adults with growth hormone deficiency must be administered daily.
Read More: https://coherentmarketorientedblogs.blogspot.com/2021/07/north-america-is-expected-to-hold.html
